Advertisement
Advertisement
U.S. Markets close in 2 hrs 58 mins
Advertisement
Advertisement
Advertisement
Advertisement

Sunshine Biopharma, Inc. (SBFM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0492-0.0018 (-3.53%)
As of 12:45PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0510
Open0.0505
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0480 - 0.0525
52 Week Range0.0420 - 0.3140
Volume488,683
Avg. Volume2,202,314
Market Cap25.355M
Beta (5Y Monthly)-3.13
PE Ratio (TTM)N/A
EPS (TTM)-0.0320
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Sunshine Biopharma Announces $1,361,000 in Debt Reduction

    MONTREAL, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that on December 20, 2021, the Company issued 2,904,833 shares of Common Stock in favor of RB Capital Partners, Inc. (“RB Capital”) in connection with the conversion of $1,361,000 in convertible debt at an average conversion price of $0.47 per share. The total debt remaining on

  • GlobeNewswire

    Sunshine Biopharma Expands Board of Directors

    Independent Directors Added as Part of Company’s Application Process to Uplist to NasdaqMONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has expanded its board of directors from three to five and has appointed three new, independent directors. The three new directors are: Mr. Andrew Tesley, Esq, Mr. JD Kish, CPA and Dr

  • GlobeNewswire

    Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases

    MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a patent application for a potential new treatment for neurodegenerative disorders. Sunshine Biopharma’s patent application contains experimental results showing that certain mRNA molecules provide protective effects against oxidative stress in differentiated n

Advertisement
Advertisement